We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bausch Health Cos | NYSE:VRX | NYSE | Ordinary Share |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 23.40 | 0.00 | 01:00:00 |
From May 2019 to May 2024
By Inti Landauro
PARIS--Valeant Pharmaceuticals International Inc. (VRX.T) is to buy the U.S. ophthalmic diagnostics unit of French biotech firm Nicox SA (COX.FR) for up to $20 million, the French firm said Monday in a statement.
According to the deal reached by the two companies, Valeant will pay Nicox $10 million in cash and up to $10 million in several installments if sales-based milestones are reached, Nicox said.
The acquisition comes as Valeant is pushing to buy Allergan, the maker of Botox, in a deal worth more than $50 million.
Write to Inti Landauro at inti.landauro@wsj.com
Access Investor Kit for Valeant Pharmaceuticals International, Inc.
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=CA91911K1021
Access Investor Kit for Nicox SA
Visit http://www.companyspotlight.com/partner?cp_code=P479&isin=FR0000074130
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Valeant Pharma Chart |
1 Month Valeant Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
